Metagenomi Therapeutics, Inc. (NasdaqGS: MGX)
Health Care · Biotechnology · US
$0.81
-1.30% today · -71.0% 1Y
Metagenomi Therapeutics, Inc. (NasdaqGS: MGX) operates in the Biotechnology industry within the Health Care sector. The company is valued at $30.43M and employs 113 people.
Over the last twelve months the share price has lost 71.0%, trading between 0.77 and 3.00.
Tweenvest scores Metagenomi Therapeutics, Inc. across four factors: quality 38/100, value 53/100. Its strongest factor is value.
MGX price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $30.43M
- Revenue (TTM)
- $13.56M
- P/E
- —
- EPS
- -2.49
- Dividend yield
- —
- Beta (5Y)
- 0.70
- 52-week high
- $3.00
- 52-week low
- $0.77
- Avg volume (3M)
- —
- Shares outstanding
- 37.78M
- Employees
- 113
- Next earnings
- —
About Metagenomi Therapeutics, Inc.
Metagenomi, Inc. operates as a biotechnology company focused on gene editing, committed to developing therapeutic solutions for patients. The company utilizes a distinctive genome editing toolkit, sourced from metagenomics, for its development efforts within the United States. This advanced toolkit comprises programmable nucleases, base editors, and sophisticated RNA and DNA-mediated integration systems, notably prime editing and CRISPR-associated transposases. Metagenomi has established several key collaborations: a strategic alliance with ModernaTX, Inc. to explore new genome editing systems for in vivo human therapeutic applications; a development and licensing agreement with Affini-T Therapeutics, Inc. to create and commercialize gene-edited T-cell receptor therapies for human cancer; and a partnership with Ionis Pharmaceuticals, Inc. to research, develop, and market investigational medicines leveraging genome editing technologies. Founded in 2016, the company is based in Emeryville, California.
- ISIN
- US59102M1045
- Founded
- 2016
- Listed since
- Feb 9, 2024
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Organoidsciences Ltd.KOSDAQ: A476040 | $31.32M | ₩6,340.00 | -7.45% |
| Oncocross Co., Ltd.KOSDAQ: A382150 | $31.31M | ₩3,200.00 | -12.45% |
| Sernova Biotherapeutics IncTSX: SVA | $30.70M | CA$0.12 | 0.00% |
| Raphael Pharmaceutical Inc.OTCPK: RAPH | $30.47M | $1.51 | — |
| HLB Pep Co., Ltd.KOSDAQ: A196300 | $30.38M | ₩4,320.00 | -17.24% |
| Genenta Science S.p.A.NasdaqCM: GNTA | $30.38M | $0.63 | -0.01% |
| Aligos Therapeutics, Inc.NasdaqCM: ALGS | $30.35M | $4.86 | -8.99% |
| Immunotech Biopharm LtdSEHK: 6978 | $30.29M | HK$0.39 | -4.94% |
Figures last refreshed Oct 18, 2026.